Pneumonia & Pandemic Preparedness | Pandemic PACT Tracker

Key facts

Disease
Bacterial infection caused by Klebsiella pneumonia
Start & end year
2021
2025
Known Financial Commitments (USD)
$844,427
Funder
Gates Foundation
Research Location
Belgium
Lead Research Institution
GlaxoSmithKline Biologicals
Research Priority Alignment
N/A

Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Pathogen morphology, shedding & natural history
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable

Abstract

To characterize Klebsiella pneumoniae capsular (K) and sub-capsular (O) antigens among strains causing neonatal sepsis in low and middle-income countries

5 Publications linked via Europe PMC

Last Updated:4 days ago

View all publications at Europe PMC

Association of serum antibody to serotype-specific capsular (K), lipopolysaccharide (O) and MrkA with risk reduction of invasive Klebsiella pneumoniae disease in young infants: an observational study

Structural elucidation and serological studies of emerging Klebsiella pneumoniae capsular polysaccharides K102 and K112.

Development and Characterization of a Ten-Plex Assay to Measure Klebsiella pneumoniae Antigen-Specific IgG in Human Sera.

The characterization of Klebsiella pneumoniae associated with neonatal sepsis in low- and middle-income countries to inform vaccine design.

Development and Application of a High-Throughput Method for the Purification and Analysis of Surface Carbohydrates from Klebsiella pneumoniae.